A strategy to pioneer key agent(s) in Cephalotaxus alkaloids against pan-cancer via filtering methodology based on integrated pharmacology.

This document explores the potential of Cephalotaxus alkaloids (CAs) as anti-cancer agents. Through data analysis using various tools and software, the study identifies heat shock protein 90 alpha family class A member 1 (HSP90AA1) as a potential target for inhibiting cancer progression and the NOD-like receptor (NLR) signaling pathway as a promising pathway for cancer treatment. The compound Nordeoxyharringtonine is identified as a potential anti-cancer mediator, and its toxicity is found to be manageable. The study suggests that Nordeoxyharringtonine can be used to validate its anti-pan-cancer effects by targeting multiple pathways. The research was supported by multiple funding sources and has been approved by all authors. [Extracted from the article]